Prevalence and Progression Rate of Interstitial Lung Abnormalities Detected on Thoracic CT: a Systematic Review and Meta-analysis

Overview

Journal Eur Radiol

Specialty Radiology

Date 2024 Jul 18

PMID 39026064

Authors

Jisun Hwang

Seulgi You

Ye Jin Lee

Joo Sung Sun

Affiliations

Soon will be listed here.

Abstract

Objectives: To estimate the pooled prevalence and progression rate of ILAs and identify the risk factors for radiological progression.

Materials And Methods: An EMBASE and PubMed search was undertaken, identifying all studies meeting the inclusion criteria performed before May 10, 2023. Random effect models were used to estimate pooled prevalence, ILA progression rates, and odds ratio for radiological progression based on radiological subtype. Subgroup analyses were performed to compare the general and high-risk populations for lung cancer. The quality of the included studies was evaluated using the risk of bias assessment tool for non-randomized studies.

Results: We analyzed 19 studies (241,541 patients) and 10 studies (1317 patients) for the pooled prevalence and progression rate of ILA, respectively. The pooled ILA prevalence was 9.7% (95% CI, 6.1-13.9%). The pooled prevalence was 6.8% (95% CI, 3.1-11.6%) and 7.1% (95% CI, 2.2-14.4%) in the general (six studies) and high-risk population for lung cancer (six studies), respectively. The pooled progression rate was 47.1% (95% CI, 29.1-65.5%). The pooled progression rate was 64.2% (95% CI, 45.0-81.2%, five studies) and 31.0% (95% CI, 8.2-60.5%, five studies) for longer (≥ 4.5 years) and shorter follow-up periods (< 4.5 years), respectively (p = 0.009). Fibrotic ILAs were significantly associated with a higher progression probability (combined OR, 5.55; 95% CI, 1.95-15.82).

Conclusions: The prevalence of ILAs was approximately 9.7%. Approximately half of the patients exhibited radiological progression, with the rate increasing over a longer follow-up period. Fibrotic ILA was a significant risk factor for radiological progression.

Clinical Relevance Statement: The prevalence of interstitial lung abnormalities (ILAs) is approximately 9.7%, with about half exhibiting progression; a longer follow-up duration and fibrotic ILAs are associated with a higher progression rate.

Key Points: ILAs are increasingly recognized as important, but few population data are available. ILAs exhibited a pooled prevalence of 9.7% with a progression rate of 47.1%. Fibrotic ILAs were associated with increased progression likelihood.

Citing Articles

Interstitial Lung Abnormalities: Unraveling the Journey from Incidental Discovery to Clinical Significance.

Gogali A, Kyriakopoulos C, Kostikas K Diagnostics (Basel). 2025; 15(4).

PMID: 40002659 PMC: 11854474. DOI: 10.3390/diagnostics15040509.

References

Hatabu H, Hunninghake G, Richeldi L, Brown K, Wells A, Remy-Jardin M . Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. Lancet Respir Med. 2020; 8(7):726-737. PMC: 7970441. DOI: 10.1016/S2213-2600(20)30168-5. View

Jin G, Lynch D, Chawla A, Garg K, Tammemagi M, Sahin H . Interstitial lung abnormalities in a CT lung cancer screening population: prevalence and progression rate. Radiology. 2013; 268(2):563-71. PMC: 3721050. DOI: 10.1148/radiol.13120816. View

Araki T, Putman R, Hatabu H, Gao W, Dupuis J, Latourelle J . Development and Progression of Interstitial Lung Abnormalities in the Framingham Heart Study. Am J Respir Crit Care Med. 2016; 194(12):1514-1522. PMC: 5215030. DOI: 10.1164/rccm.201512-2523OC. View

Putman R, Gudmundsson G, Axelsson G, Hida T, Honda O, Araki T . Imaging Patterns Are Associated with Interstitial Lung Abnormality Progression and Mortality. Am J Respir Crit Care Med. 2019; 200(2):175-183. PMC: 6635786. DOI: 10.1164/rccm.201809-1652OC. View

Grant-Orser A, Min B, Elmrayed S, Podolanczuk A, Johannson K . Prevalence, Risk Factors, and Outcomes of Adult Interstitial Lung Abnormalities: A Systematic Review and Meta-Analysis. Am J Respir Crit Care Med. 2023; 208(6):695-708. PMC: 10515575. DOI: 10.1164/rccm.202302-0271OC. View

Putman R, Hatabu H, Araki T, Gudmundsson G, Gao W, Nishino M . Association Between Interstitial Lung Abnormalities and All-Cause Mortality. JAMA. 2016; 315(7):672-81. PMC: 4828973. DOI: 10.1001/jama.2016.0518. View

Washko G, Hunninghake G, Fernandez I, Nishino M, Okajima Y, Yamashiro T . Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med. 2011; 364(10):897-906. PMC: 3074462. DOI: 10.1056/NEJMoa1007285. View

Tsushima K, Sone S, Yoshikawa S, Yokoyama T, Suzuki T, Kubo K . The radiological patterns of interstitial change at an early phase: over a 4-year follow-up. Respir Med. 2010; 104(11):1712-21. DOI: 10.1016/j.rmed.2010.05.014. View

Hunninghake G, Hatabu H, Okajima Y, Gao W, Dupuis J, Latourelle J . MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med. 2013; 368(23):2192-200. PMC: 3747636. DOI: 10.1056/NEJMoa1216076. View

10.

Sack C, Vedal S, Sheppard L, Raghu G, Barr R, Podolanczuk A . Air pollution and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis (MESA) air-lung study. Eur Respir J. 2017; 50(6). PMC: 5726423. DOI: 10.1183/13993003.00559-2017. View

11.

Sack C, Doney B, Podolanczuk A, Hooper L, Seixas N, Hoffman E . Occupational Exposures and Subclinical Interstitial Lung Disease. The MESA (Multi-Ethnic Study of Atherosclerosis) Air and Lung Studies. Am J Respir Crit Care Med. 2017; 196(8):1031-1039. PMC: 5649983. DOI: 10.1164/rccm.201612-2431OC. View

12.

Lee J, Chae K, Suh Y, Jeong W, Lee T, Kim Y . Prevalence and Long-term Outcomes of CT Interstitial Lung Abnormalities in a Health Screening Cohort. Radiology. 2022; 306(2):e221172. DOI: 10.1148/radiol.221172. View

13.

Chae K, Lim S, Seo J, Hwang H, Choi H, Lynch D . Interstitial Lung Abnormalities at CT in the Korean National Lung Cancer Screening Program: Prevalence and Deep Learning-based Texture Analysis. Radiology. 2023; 307(4):e222828. DOI: 10.1148/radiol.222828. View

14.

Hino T, Hida T, Nishino M, Lu J, Putman R, Gudmundsson E . Progression of traction bronchiectasis/bronchiolectasis in interstitial lung abnormalities is associated with increased all-cause mortality: Age Gene/Environment Susceptibility-Reykjavik Study. Eur J Radiol Open. 2021; 8:100334. PMC: 7960545. DOI: 10.1016/j.ejro.2021.100334. View

15.

Zhang Y, Wan H, Richeldi L, Zhu M, Huang Y, Xiong X . Reticulation Is a Risk Factor of Progressive Subpleural Nonfibrotic Interstitial Lung Abnormalities. Am J Respir Crit Care Med. 2022; 206(2):178-185. DOI: 10.1164/rccm.202110-2412OC. View

16.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

17.

Kim S, Park J, Lee Y, Seo H, Sheen S, Hahn S . Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol. 2013; 66(4):408-14. DOI: 10.1016/j.jclinepi.2012.09.016. View

18.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

19.

IntHout J, Ioannidis J, Borm G . The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014; 14:25. PMC: 4015721. DOI: 10.1186/1471-2288-14-25. View

20.

Schwarzer G, Chemaitelly H, Abu-Raddad L, Rucker G . Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. Res Synth Methods. 2019; 10(3):476-483. PMC: 6767151. DOI: 10.1002/jrsm.1348. View